Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 23

1.

Hemorrhagic radiation cystitis.

Mendenhall WM, Henderson RH, Costa JA, Hoppe BS, Dagan R, Bryant CM, Nichols RC, Williams CR, Harris SE, Mendenhall NP.

Am J Clin Oncol. 2015 Jun;38(3):331-6. doi: 10.1097/COC.0000000000000016. Review.

PMID:
24322335
2.

Clinical outcomes of WF10 adjunct to standard treatment of diabetic foot ulcers.

Yingsakmongkol N.

J Wound Care. 2013 Mar;22(3):130-2, 134-6.

PMID:
23665731
3.

Effect of WF10 (immunokine) on diabetic foot ulcer therapy: a double-blind, randomized, placebo-controlled trial.

Yingsakmongkol N, Maraprygsavan P, Sukosit P.

J Foot Ankle Surg. 2011 Nov-Dec;50(6):635-40. doi: 10.1053/j.jfas.2011.05.006. Epub 2011 Jul 1.

PMID:
21723750
4.

WF10 stimulates NK cell cytotoxicity by increasing LFA-1-mediated adhesion to tumor cells.

Kühne L, Konstandin M, Samstag Y, Meuer S, Giese T, Watzl C.

J Biomed Biotechnol. 2011;2011:436587. doi: 10.1155/2011/436587. Epub 2011 May 3.

5.

Management of radiation cystitis.

Smit SG, Heyns CF.

Nat Rev Urol. 2010 Apr;7(4):206-14. doi: 10.1038/nrurol.2010.23. Epub 2010 Mar 9. Review.

PMID:
20212517
6.

An avian live attenuated master backbone for potential use in epidemic and pandemic influenza vaccines.

Hickman D, Hossain MJ, Song H, Araya Y, Solórzano A, Perez DR.

J Gen Virol. 2008 Nov;89(Pt 11):2682-90. doi: 10.1099/vir.0.2008/004143-0.

8.
9.

A phase II study to evaluate WF10 in patients with late hemorrhagic radiation cystitis and proctitis.

Veerasarn V, Boonnuch W, Kakanaporn C.

Gynecol Oncol. 2006 Jan;100(1):179-84. Epub 2005 Sep 19.

PMID:
16169580
10.

Reduced recurrence of late hemorrhagic radiation cystitis by WF10 therapy in cervical cancer patients: a multicenter, randomized, two-arm, open-label trial.

Veerasarn V, Khorprasert C, Lorvidhaya V, Sangruchi S, Tantivatana T, Narkwong L, Kongthanarat Y, Chitapanarux I, Tesavibul C, Panichevaluk A, Puribhat S, Sangkittipaiboon S, Sookpreedee L, Lertsanguansinchai P, Phromratanapongse P, Rungpoka P, Trithratipvikul S, Lojanapiwat B, Ruangdilokrat S, Ngampanprasert P.

Radiother Oncol. 2004 Nov;73(2):179-85.

PMID:
15542165
11.

Differential effects on innate versus adaptive immune responses by WF10.

Giese T, McGrath MS, Stumm S, Schempp H, Elstner E, Meuer SC.

Cell Immunol. 2004 Jun;229(2):149-58.

PMID:
15474529
12.

Immunosuppression in xenotransplantation with Wf10.

Kemp K, Dieperink H, Hansen A, Horn T, Johansen A, Jensen J, Kemp G, Larsen S, Lillevang S, Svendsen M, Freilow E, Kuhlmann IL, Kemp E.

Pharmacol Toxicol. 2002 Jun;90(6):346-8. No abstract available.

PMID:
12403058
13.

Development of WF10, a novel macrophage-regulating agent.

McGrath MS, Kahn JO, Herndier BG.

Curr Opin Investig Drugs. 2002 Mar;3(3):365-73.

PMID:
12054081
14.

High-dose stabilized chlorite matrix WF10 prolongs cardiac xenograft survival in the hamster-to-rat model without inducing ultrastructural or biochemical signs of cardiotoxicity.

Hansen A, Kemp K, Kemp E, Bouchelouche K, Bouchelouche P, Dieperink H, Horn T, Larsen S.

Pharmacol Toxicol. 2001 Aug;89(2):92-5.

PMID:
11555326
15.

Chlorite-hemoprotein interaction as key role for the pharmacological activity of the chlorite-based drug WF10.

Schempp H, Reim M, Dornisch K, Elstner EF.

Arzneimittelforschung. 2001;51(7):554-62.

PMID:
11505786
16.

Drug watch.

Whitson S.

Posit Aware. 1999 Jan-Feb;10(1):18-9.

PMID:
11366516
17.

An American study of WF10 looks promising.

[No authors listed]

TreatmentUpdate. 1998 Sep;10(7):1-3. English, French.

PMID:
11365779
18.

WF10 in xenotransplantation-a potential new approach.

Kemp E, Dieperink H, Horn T, Johansen A, Jensen J, Kemp G, Larsen S, Lillevang S, Svendsen M, Freilow E, Kuhlmann I, Kemp K.

Transplant Proc. 2000 Aug;32(5):1018-9. No abstract available.

PMID:
10936328
19.
20.

Effect of WF10 (TCDO) on antigen presentation.

McGrath MS, Benike C, Kuehne FW, Engleman E.

Transplant Proc. 1998 Dec;30(8):4200-4. No abstract available.

PMID:
9865348
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk